Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

antiCAFing

Financiado

Harnessing Stromal Fibroblasts to Reduce Resistance and Improve Colon Cancer The...

Harnessing Stromal Fibroblasts to Reduce Resistance and Improve Colon Cancer Therapeutics Refractory tumors and emergence of drug resistance are the most important challenges in cancer therapeutics. The non-cancerous determinants of therapeutic response and particularly the role of the tumor microenvironment (TME) in r... ver más

31/08/2027

CSIC

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-08-08

ERC-2021-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CSIC

2.00M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-096778-A-I00 IDENTIFICACION Y CARACTERIZACION DE ESTRATEGIAS PARA MODULAR... 169K€ Cerrado

RTI2018-095672-B-I00 TERAPIAS MOLECULARES DIRIGIDAS AL MICROAMBIENTE EN FIBROSIS... 145K€ Cerrado

PID2021-128107OB-I00 ESTRATEGIAS PARA SILENCIAR LA COMUNICACION ENTRE LOS FIBROBL... 327K€ Cerrado

PID2020-120073GB-I00 MODIFICAR LA RIGIDEZ DEL TEJIDO CANCEROSO PARA DETENER SU PR... 125K€ Cerrado

SAF2017-84976-R REGULACION DE LA PLASTICIDAD DE LAS CELULAS TUMORALES EN LA... 182K€ Cerrado

PID2019-106666RB-I00 ANALISIS MULTIFACTORIAL DE LA RESISTENCIA A FARMACOS ANTI-TU... 218K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2022-08-08
Fecha Fin: 2027-08-31

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Presupuesto del proyecto 2M€

Descripción del proyecto Refractory tumors and emergence of drug resistance are the most important challenges in cancer therapeutics. The non-cancerous determinants of therapeutic response and particularly the role of the tumor microenvironment (TME) in resistance are poorly understood. I previously described the crucial role of cancer-associated fibroblasts (CAFs) in key tumorigenic processes, including matrix remodeling, cancer cell invasion and growth. Importantly, these aggressive CAF phenotypes are controlled by mechanical reprogramming and mechanotransduction pathways. Within therapeutic resistance contexts, I hypothesize that preexistent and therapy-induced aberrant activation of mechanotransduction signaling in CAFs leads to the generation of refractory TMEs affecting cancer cell signaling and the behavior of accessory stromal cells such as endothelial and immune cells. As a result, tumors will present: (i) abnormal vasculature associated with reduced drug perfusion and chemotherapy efficacy; (ii) increased production of pro-survival signals affecting targeted therapy; and (iii) inactivation of cytolytic T cells and reduced responses to immunotherapy. I propose that CAF-based biomarkers will improve our capacity to identify patients most likely to respond to these therapeutics. In addition, targeting mechanotransduction in CAFs will significantly increase efficacy in non-responders. Focusing in colorectal cancer, I will use patient-derived CAFs as a tractable system and organ-on-chip, in vitro and preclinical models of CAF-mediated resistance, and combinatorial chemistry to systematically elucidate the molecular and biological features conferring CAFs their privileged therapy-resistance properties. This will illuminate novel and general mechanisms whereby TME characteristics influence tumorigenesis, and inform the development of refined biomarkers to stratify patients and next generation combinatorial therapies (including anti-CAF therapies) with reduced risk of recurrence.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores